Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease

Reuters Staff  |  Issue: November 2019  |  October 2, 2019

NEW YORK (Reuters Health)—Nintedanib dramatically slows lung deterioration in patients with progressive fibrosing interstitial lung diseases, according to a new randomized study.1

Nintedanib has already been shown to be effective against idiopathic pulmonary fibrosis (IPF). The new trial, funded by the manufacturer, Boehringer Ingelheim, and presented t the European Respiratory Society International Congress 2019 in Madrid, was designed to assess its effectiveness against a broad range of fibrosing lung diseases in 663 volunteers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

After a year of treatment, nintedanib patients had an adjusted rate of decline of 80.8 mL in their forced vital capacity (FVC) compared with a decline of 187.8 mL with placebo (P<0.001).

In patients with an unusual interstitial pneumonia (UIP) like fibrotic pattern, the FVC drop was 82.9 mL vs. 211.1 ml with placebo (P<0.001).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers’ “apparent success in this trial suggests a final common pathway to fibrosis,” Hilary Goldberg, MD, of Brigham and Women’s Hospital, Boston, writes in an editorial in the New England Journal of Medicine, online Sept. 29.2

However, diarrhea was nearly three times more common in the nintedanib group, with rates of 66.9% with the drug and 23.0% with placebo.

And abnormalities in liver-function testing were seven times more common with the drug, with rates of 1.8% for placebo and 13.0% for nintedanib, which is sold under the brand name Ofev.

Additionally, the measures of quality of life used by the researchers did not show a meaningful difference between the two groups.

The INBUILD study was done at 153 sites in 15 countries. The research team enrolled patients with a progressive fibrotic disease other than IPF. People being treated with azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, cyclophosphamide, rituximab or more than 20 mg per day of glucocorticoids were excluded.

Patients who had troublesome side effects could suspend their therapy or get a lower dose of 100 mg twice daily instead of the usual 150 mg dose.

The company analyzed the data.

The researchers separately assessed patients with UIP, because of previous research suggesting that fibrosis might develop faster in that group. Sixty two percent fell into that category.

The rate of death or acute exacerbation of interstitial lung disease at one year was 7.8% with nintedanib and 9.7% with placebo, a non-significant difference.

The overall rates of adverse events and serious adverse events were comparable in the two groups. However, 19.6% in the nintedanib group discontinued their treatment compared with 10.3% who received placebo.

Side effects led to a permanent reduction in dose among 33.1% of nintedanib patients compared with 4.2% of those getting placebo.

“The use of nintedanib may slow the disease progression, but our challenge for the future is to design studies that identify earlier targets to prevent the establishment of this still highly morbid condition,” Dr. Goldberg says.


References

  1. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019 Sep 29. [Epub ahead of print]
  2. Goldberg HJ. Understanding progressive fibrosing interstitial lung disease through therapeutic trials. N Engl J Med. 2019 Sep 29. [Epub ahead of print]

Page: 1 2 | Multi-Page
Share: 

Filed under:Drug Updates Tagged with:ILDInterstitial Lung Diseaselung diseaselungsnintedanib

Related Articles

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    What Causes Nephrogenic Systemic Fibrosis?

    September 1, 2007

    Imaging studies and kidney problems may trigger this gadolinium-induced fibrosing syndrome

    FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations

    December 18, 2019

    Aquir / shutterstock.com The U.S. Food & Drug Admin­istration (FDA) approved nintedanib for systemic sclerosis associated interstitial lung disease (SSc-ILD) on Sept. 6 after a randomized, controlled trial (SENSCIS) demonstrated significant benefit against placebo.1 At a cost of $96,000 per year, treatment reduced the adjusted annual rate of change in forced vital capacity (FVC) from…

    Advances in Connective Tissue Disease-Associated Interstitial Lung Disease

    December 1, 2021

    ACR Convergence 2021—The past year has been an exciting time for researchers and clinicians focused on the topic of connective tissue disease-associated interstitial lung disease (CTD-ILD), with advances in our understanding of these disorders and newly approved medications for their treatment. At the ACR Convergence 2021 annual Review Course, Kristin Highland, MD, MSCR, director of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences